Related Experiment Video
Updated: Oct 23, 2025
Preparation of Mitochondrial Enriched Fractions for Metabolic Analysis in Drosophila
Published on: September 30, 2015
Differential responses of AMD mitochondrial DNA haplogroups to PU-91, a mitochondria-targeting drug
Andrea Bao1, Sonali Nashine1, Shari Atilano1
1Department of Ophthalmology, Gavin Herbert Eye Institute, University of California Irvine, Irvine, CA 92697, USA.
Abstract:
Mitochondrial DNA (mtDNA) dysfunction and variation in mtDNA haplogroups play a key role in the etiology of Age-related Macular Degeneration (AMD). This study examined the response(s) of AMD ARPE-19 transmitochondrial cybrids having U, K, and J mtDNA haplogroups to treatment with a mitochondria-targeting PU-91 drug. PU-91 exerts its cytoprotective effects by upregulating PGC-1α (Peroxisome proliferator-activated receptor-gamma coactivator (PGC)-1alpha) which is a primary regulator of the mitochondrial biogenesis pathway. The effects of PU-91 drug were determined using cell-based assays and gene expression analyses. Our study revealed that AMD cybrids with different mtDNA haplogroups i.e., U, K, J haplogroups respond differentially to PU-91 drug treatment; and that the PU-91 drug increases viable cell number, improves mitochondrial health, and protects AMD cybrids against oxidative stress across the board irrespective of their haplogroup variation. This study suggests that mtDNA haplogroups may contribute to the differential responses of AMD cybrid cells to PU-91 drug in vitro and may also influence AMD patients' responses to drug treatment.
Insights
Mitochondrial DNA (mtDNA) haplogroups influence Age-related Macular Degeneration (AMD) cell responses to the PU-91 drug. However, PU-91 universally enhances cell viability and mitochondrial health in AMD cybrids.
Area of Science:
- Ophthalmology
- Genetics
- Cell Biology
Background:
- Mitochondrial DNA (mtDNA) dysfunction and haplogroup variations are implicated in Age-related Macular Degeneration (AMD) pathogenesis.
- Transmitochondrial cybrids offer a model to study mtDNA's role in AMD.
Purpose of the Study:
- To investigate the differential responses of AMD cybrids with specific mtDNA haplogroups (U, K, J) to the mitochondria-targeting drug PU-91.
- To assess PU-91's cytoprotective effects mediated by PGC-1α upregulation.
Main Methods:
- Utilized AMD ARPE-19 transmitochondrial cybrids carrying U, K, and J mtDNA haplogroups.
- Administered the mitochondria-targeting drug PU-91.
- Performed cell-based assays and gene expression analyses to evaluate drug effects.
Main Results:
- AMD cybrids exhibited differential responses to PU-91 based on their mtDNA haplogroups (U, K, J).
- PU-91 treatment universally increased viable cell number, improved mitochondrial health, and protected against oxidative stress.
- PU-91 upregulated Peroxisome proliferator-activated receptor-gamma coactivator (PGC)-1α, a key regulator of mitochondrial biogenesis.
Conclusions:
- mtDNA haplogroups may influence the in vitro response of AMD cybrid cells to PU-91.
- These findings suggest that mtDNA haplogroups could potentially impact AMD patients' responses to PU-91 drug therapy.
Related Concept Videos
02:59Animal Mitochondrial Genetics
01:46Electron Transport Chain: Complex I and II
ROS generation is regulated and maintained at moderate levels necessary...